ANAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ANAB is a good buy right now for a beginner with a long-term horizon and $50,000-$100,000 to invest. The stock has a bullish technical setup, supportive analyst sentiment, and a clear event-driven catalyst from the upcoming GSK dispute court date. With no negative recent news and insider/hedge fund activity neutral, the current price appears to offer a reasonable entry rather than a stretched one. I would rate it as a buy now, especially for a long-term position.
ANAB's trend is constructive. MACD histogram is positive at 0.921, though slightly contracting, which still supports upward momentum. RSI_6 at 65.331 is near the upper end of neutral but not yet overbought. The moving averages are bullish with SMA_5 > SMA_20 > SMA_200, confirming an uptrend. Price at 59.68 is above pivot 57.23 and approaching R1 at 61.386, with further resistance at 63.954. The short-term trend remains positive, and the swing setup has already triggered a valid entry signal on 2026-06-15, with the stock up 2.95% since then.
Recent analyst upgrades and higher price targets are supportive, especially Leerink raising its target to $90 and UBS/Barclays increasing targets while maintaining positive ratings. The biggest catalyst is the upcoming July 14-17 court date tied to the GSK dispute, which multiple analysts view as potentially favorable for ANAB. The company has also been repositioned as a pure royalty management story after the TRAX spinoff, which the street sees as simplifying the investment case and emphasizing cash flow from Jemperli royalties. No recent negative news was reported.
There has been no news in the last week, so near-term fresh momentum is limited. Analyst targets have been mixed over time, with UBS and Barclays previously cutting targets before later raising them again, showing some uncertainty in valuation. The options market also shows a high put volume ratio on the day, suggesting some traders are hedging ahead of event risk. The latest financial snapshot was unavailable, so the most recent quarter's fundamentals cannot be directly confirmed here.
Latest quarter financials were not provided because the financial snapshot returned an error, so I cannot assess precise revenue or earnings growth from the newest quarter season. Based on analyst commentary, Q1 Jemperli collaboration revenue came in below expectations, but the broader trend remains focused on monetizing the Jemperli royalty stream after the TRAX spinoff. The market appears to be valuing ANAB more as a royalty income story than a traditional growth biotech.
Analyst sentiment is clearly positive overall. Recent ratings are mostly Buy/Outperform/Overweight, with Leerink, UBS, Barclays, and Piper Sandler all constructive. Price targets have generally moved higher recently, including Leerink to $90, UBS to $76, Barclays to $75, and Piper Sandler to $93. The street’s pros view is that ANAB has upside from Jemperli royalties and possible favorable court outcomes, while the cons view is that valuation depends heavily on the dispute outcome and royalty durability.
